Mode
Text Size
Log in / Sign up
N/A N=200 Randomized Single-blind Prevention

PICO Breast Reduction Clinical Study Looking at Incision Healing Complications

Delayed Healing

Enrolled (actual)
200
Serious AEs
2.3%
Results posted
Feb 2020
Primary outcome: Primary: Number of Participants Experiencing Incision Healing Complications up to Day 21 Postoperatively — 113; 86; 123; 76 participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
PICO (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
Female
Sponsor
Smith & Nephew, Inc.
Primary completion
Apr 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants Experiencing Incision Healing Complications up to Day 21 Postoperatively
113; 86; 123; 76
SECONDARY
Number of Participants Experiencing Postsurgical Incision Healing Complications (Dehiscence) Occurring up to Day 21 Postoperatively
32; 165; 52; 145
SECONDARY
Number of Participants Experiencing Postsurgical Incision Healing Complications (Infection) Occurring up to Day 21 Postoperatively
4; 193; 6; 191
SECONDARY
Number of Participants Experiencing Postsurgical Incision Healing Complications (Delayed Healing) Occurring Within 7 Days Postoperatively
102; 97; 103; 96
SECONDARY
Number of Participants Experiencing Postsurgical Incision Healing Complications (Delayed Healing) Occurring Within 10 Days Postoperatively
64; 135; 64; 135
SECONDARY
Aesthetic Appearance (Cosmesis) and Scar Quality at 90 Days Postoperatively
3; 3; 16; 18; 15; 19
SECONDARY
Number of Skin, Nipple and Areola Necrosis Occurring up to and 21 Days Postoperatively
2; 7; 2; 1
SECONDARY
Number of Hematoma's Occurring up to and 21 Days Postoperatively
2; 3
SECONDARY
Number of Wounds Showing 100% Closure Occurring up to and 21 Days Postoperatively
155; 134

Summary

The purpose of this study is to see if the use of a single-use negative pressure wound therapy system (NPWT) will have an effect on the reduction of post-surgical incision healing complications following breast reduction surgery and to assess the medium-term aesthetic appearance and quality of the resultant scar, compared with standard of care dressings.

Eligibility Criteria

Inclusion Criteria

  • Female patient's ≥ 18 years old
  • The patient is able to understand the trial and is willing to consent to the trial
  • Patient has undergone an elective surgical procedure for bilateral reduction mammoplasty
  • Patients postsurgical incisions are of similar length

Exclusion Criteria

  • Pregnant or lactating females
  • Patients on steroids or other immune modulators known to impact healing which may affect scar appearance
  • Patients with tattoos in the area of the incisions
  • Patients with skin conditions (Cutis laxa etc.) that would result in poor healing or widened scars
  • Patients with a known significant history of scar problems i.e. hypertrophic scaring or keloids
  • Patients who in the opinion of the investigator may not complete the study for any reason
  • Patients with a known history of poor compliance with medical treatment
  • Patients who have participated in this trial previously and who were withdrawn
  • Patients with known allergies to product components (silicone adhesives and polyurethane films (direct contact with wound), acrylic adhesives (direct contact with skin), polyethylene fabrics and super-absorbent powders (polyacrylates) (within the dressing)
  • Incisions that are actively bleeding
  • Exposure of blood vessels, organs, bone or tendon at the base of the reference wound
  • Incisions > 12 inches (30cm) max linear dimension
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01640366). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search